English Policy Brief Collection – Volume 1
The English Policy Brief Collection (Volume 1) presents a selection of policy briefs published by the HITAP Foundation. These policy briefs have been ...Read more
The English Policy Brief Collection (Volume 1) presents a selection of policy briefs published by the HITAP Foundation. These policy briefs have been ...Read more
Thailand has successfully implemented economic evaluation to inform the inclusion of new, branded medicines within its National List of Essential Medi ...Read more
Open data is widely recognized as valuable, especially during the COVID-19 pandemic, highlighting the need for up-to-date information systems, leading ...Read more
Because of their rarity, rare diseases are often treated with what the industry refers to as ‘orphan drugs’. These group of drugs are quite expensive ...Read more
Cost-effectiveness and availability of alternative treatment options play a crucial role in the listing of new medicines in South Korea. However, high ...Read more
This policy brief summarise findings from literature review on definition of 'rare disease,' and the use of HTA to support policy decisions around rar ...Read more
This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare di ...Read more
The Cancer Drug Fund (CDF) is a dedicated source of funding in England for increasing patient access to high-cost cancer drugs, with a fixed budget of ...Read more
Cancer Drug Fund (CDF) เป็นกองทุนในอังกฤษเพื่อเพิ่มการเข้าถึงยารักษามะเร็งที่มีราคาสูง กองทุนนี้เริ่มดำเนินการมาตั้งแต่ พ.ศ. 2559 และมีงบประมาณ 340 ล้ ...Read more
Horizon Scanning (HS) is the process of identifying new and emerging technologies before uptake into practice to evaluate the potential impact to info ...Read more